Navigation Links
Isis Reports Financial Results and Highlights for Fiscal year 2007
Date:3/13/2008

successes, we have the opportunity to aggressively advance our drugs in development, with significant data milestones planned for our two most advanced drugs, mipomersen and ISIS 113715, and expand our pipeline with two to four new drugs. Our partnering successes over the last year have created substantial interest in Isis and our technology, which we plan to exploit with new strategic relationships. In short, we believe 2007 is just the beginning of value creation from Isis' antisense platform and look forward to an exciting upcoming year," concluded Ms. Parshall.

Drug Development Highlights

Isis' cardiovascular franchise matured appreciably during the last year, with mipomersen at the forefront. The clinical success of mipomersen has added significant value to the entire drug development pipeline.
* Mipomersen (formerly ISIS 301012) continues to demonstrate an

excellent safety and efficacy profile supported by strong Phase 2

clinical results in all patient populations tested. As a result, Isis

has initiated registration studies of mipomersen in Familial

Hypercholesterolemia patients.

* Isis established a strategic alliance with BMS for the discovery and

development of antisense drugs targeting PCSK9, an important regulator

of the LDL-receptor.

* Isis initiated IND-enabling studies of ISIS 353512, an antisense drug

that targets C-reactive protein, in partnership with the Korea

Institute of Technology. Isis' metabolic disease franchise continued to expand with the addition of new diabetes drugs into development, and new research efforts toward attractive targets for the treatment of obesity.
* Isis continued Phase 2 studies of ISIS 113715 for the treatment of

type 2 diabetes in patients on stable sulfonylurea treatment. In

humans and preclinical studies, ISIS 113715 demonstrated reductions in

blood
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Supply & Demand Chain Executive Magazine has ... Know” in the supply chain industry, and we are ... team were included on this year’s list! Russ King ... due to their hard work, their commitment to excellence, ... resolving client needs and challenges. , Russ ...
(Date:3/5/2015)... 05, 2015 Dr. Jonathan Glashow a ... ) has been named by Castle Connolly ... area. Dr. Glashow has been selected by Castle Connolly ... the top specialty care doctors in the tri-state metropolitan ... Connolly program, which carefully screens and selects doctors through ...
(Date:3/5/2015)... As a result of the American ... Clearstream, LLC ’s products, services and company philosophies, ... products—led by their mPulse Hand Sanitizer—fits the core ... The AAPA—which represents a profession comprising than 100,000 ... specialties in the U.S.—advocates and educates on behalf ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 Today, ... now running on 100% pollution-free electricity through a ... , As an Arcadia Power Clean Energy ... (EPA) Green Power Partnership requirements, joining national brands ... also purchase clean energy. Earth Source Organics joins ...
(Date:3/5/2015)... Park, California (PRWEB) March 05, 2015 ... (JCAP) last week released a special issue ... in the field of PANDAS (Pediatric Autoimmune Neuropsychiatric ... Neuropsychiatric Syndromes), an autoimmune reaction triggered by infections ... lyme, which result in inflammation of the child's ...
Breaking Medicine News(10 mins):Health News:MEBC Leaders Awarded Supply Demand Chain Executive Pros to Know Title For 2015 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 2Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 3Health News:Clearstream’s Line of MediDefense Antimicrobial Products Scores Affinity Partnership With American Academy of Physician Assistants (AAPA) 4Health News:Earth Source Organics to Run on Clean Energy from Arcadia Power 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 2Health News:Controversial Childhood Illness PANDAS the Focus of a Special Medical Journal Issue 3
... has been found that elders in hospitals and care homes are ... this, many of them are said to be in hunger// for ... Ivan Lewis. ,Commencing the ‘Dignity for older people’ campaign ... people should be thoroughly understood. When the food is kept far ...
... Pennsylvania School of Medicine have described a new type ... the patient's thoughts, providing two-way signaling for motor control ... at a junction now of developing a new approach ... Smith, MD, Professor of Neurosurgery and Director of the ...
... Scientists have unlocked the secrets of a deadly superbug that attacks ... ,The news is a vital first step in attempts to ... resistant to current antibiotic treatments. ,Already responsible for ... stages of an epidemic that could result in a massive death ...
... study, published in the March 1, 2007 issue of CANCER, ... termination of this highly effective breast cancer drug may negatively ... that over one third of women have ceased tamoxifen treatment. ... quarter of women treated for breast cancer stop tamoxifen within ...
... traits shape up in natural populations,// but one is led ... Two theories have tried to address this challenge – the ... ,The theory of hitchhiking has indicated that genes ... in natural populations when they "hitch a ride" with healthier ...
... whatever the color”, says Dr.Clive Anderson, consultant dermatologist and ... address is part of a move to get Jamaicans ... of the island’s youth resort to bleaching or lightening ... ,Government health officials plan to launch a ...
Cached Medicine News:Health News:New Ideas on Developing Thought-Controlled Artificial Limbs 2Health News:Tamoxifen Discontinuation Rates Surprisingly High 2Health News:The Evolution of Costly Traits 2
(Date:3/5/2015)... 2015 Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today it will report fourth ... open on Wednesday, March 25, 2015, followed by ... Eastern. Conference Call & Webcast: ... Domestic: , 800-753-9057International: , 913-981-5571Conference ID: , ...
(Date:3/5/2015)... und TÜBINGEN, Deutschland, 5. März ... Gates Stiftung und das deutsche biopharmazeutische Unternehmen ... 46 Millionen Euro (52 Millionen US-Dollar) in ... Bereich der medizinisch angewandten Messenger-RNA (mRNA). Auf ... Ansätze zur Behandlung von Krankheiten und zum ...
(Date:3/5/2015)...  As the pharmaceutical industry works to address ... professionals are placing a significant emphasis on company ... by LRN, the leader in Ethics & Compliance ... respondents expressed that clarity on company values is ... training programs (57%), trumping understanding of the PhRMA ...
Breaking Medicine Technology:Vermillion to Report Fourth Quarter and Year-End 2014 Financial Results and Host an Investor Conference Call on March 25 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 2Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 3Bill & Melinda Gates Stiftung investiert in CureVac zur Entwicklung innovativer Impfstoffe 4Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3
... 2010 Results from the VeriStrat analysis of a ... with sorafenib in patients with advanced non-small cell lung ... Symposium on Molecular Targets in Cancer Therapeutics being held ... the VU Medical Center, Amsterdam, The Netherlands.  The intention ...
... SAN DIEGO, Nov. 19, 2010 Marshall Edwards, Inc.(Nasdaq: ... the clinical development of novel anti-cancer therapeutics, announced today ... the Listing Qualifications Staff of The NASDAQ Stock Market ... $10 million stockholders, equity requirement for continued listing on ...
Cached Medicine Technology:VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 2VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy 3Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 2Marshall Edwards Receives NASDAQ Notice Of Non-Compliance; Intends To Request Hearing 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: